T he thiazolidinedione (TZD) class of medications has been associated with increased risk for peripheral oedema, as well as incident and worsening heart failure (HF). The mechanism of these observed effects remains unclear. Here we present the rationale and study design for a randomised clinical trial designed to evaluate the cardiac effects of rosiglitazone on integrated cardiovascular performance, cardiac structure and function.
Introduction
Since their clinical introduction in 1994, the thiazolidinediones (TZD) class of drugs has become one of the most commonly prescribed medical therapies to treat hyperglycaemia in type 2 diabetes mellitus (T2DM). 1 As the clinical use of TZDs has increased, a number of signals have emerged regarding increased risk for peripheral oedema, and more ominously, increased risk for the development of new or worsening heart failure (HF). These observations have spawned a cascade of commentaries and meta-analyses in the peer-reviewed literature, [2] [3] [4] [5] position statements from professional organisations, 6 and product labelling language, initially moderately cautionary and more recently amplified under guidance of the Food and Drugs Administration (FDA) with regard to the HF risk associated with this class of medications. 7, 8 While the cautionary advice has been fairly rigorous, the mechanistic and clinical understanding of the observed peripheral oedema and worsening HF symptoms remains rudimentary. Few studies have systematically assessed the effects of the TZDs on cardiac structure and function, [9] [10] [11] and those that have done so suffer from important limitations of study design, assessment methods and trial execution. In the context of these limited available data, no study to date has demonstrated pernicious effects on cardiomyocytes or cardiac structure or function associated with TZD treatment; the bulk of the data support either neutral or beneficial effects in this regard and implicate plasma volume expansion as the basis for the observed peripheral oedema and HF. [12] [13] [14] In light of this apparent clinical paradox and the uncertain effects of TZDs on cardiac structure and function, we designed a placebo-controlled trial to assess the effects of rosiglitazone, a TZD, versus placebo on peak oxygen consumption, the gold-standard measure of integrated cardiovascular performance; these measurements will be complemented by serial clinical assessments by a cardiologist and measurement of circulating brain natriuretic peptide (BNP). In a subset of patients, we also plan to assess the effects of rosiglitazone on magnetic resonance imaging (MRI) measures of cardiac structure and function and magnetic resonance spectroscopy (MRS) analysis of intramyocardial triglyceride content.
Methods

Study objectives
The study objectives are summarised in table 1. The primary objective of this study is to determine the effects of rosiglitazone versus placebo on integrated cardiovascular performance (measured by peak VO 2 ) during peak treadmill cardiopulmonary exercise testing (CPX) in a population with type 2 diabetes mellitus (T2DM) and at increased risk for congestive heart failure, based on concomitant prevalent cardiovascular disease (CVD) at study entry or the presence of at least one additional CVD risk factor.
Study design and population
The study design is a single-centre, prospective, doubleblind, randomised, parallel group, placebo-controlled study, and is designed to target a subset of individuals with T2DM at increased risk for developing HF. Subjects will be recruited from an existing research database; 15 outpatient cardiology, diabetes and continuity clinics at Parkland Health and Hospital Systems and at the University of Texas Southwestern Medical Center; and by public advertisement. The protocol was approved by the University of Texas Southwestern Medical Center Institutional Review Board, and all subjects will provide their written informed consent.
Inclusion and exclusion criteria are summarised in table 2. Subjects will be eligible if they have a diagnosis of medically treated T2DM plus either of the following: a prior diagnosis of cardiovascular disease (coronary artery disease [CAD], myocardial infarction, revascularisation, cerebrovascular accident/transient ischaemic attack, carotid or peripheral arterial disease), or have at least one additional CV risk factor (smoking, hypertension, hypercholesterolaemia, albuminuria, family history of premature CAD or documented high-sensitivity C-reactive protein [hs-CRP] > 3 mg/L). T2DM will be defined by a prior clinical diagnosis AND the current use of hypoglycaemic medical therapy. To explore for differential treatment effects according to race, efforts will be made to recruit a racially diverse population, with approximately one third each of white, black and Hispanic patients. Exclusion criteria will include treatment with a TZD within the prior six months; documented intolerance to a TZD; a history or evidence of HF; or aspartate aminotransferase or alanine aminotransferase (AST/ALT) levels greater than three times the upper limit of normal.
Treatment protocol and dosing regimens
Eligible subjects who volunteer to participate will be randomised in a 1:1 fashion, stratified by race, to either the treatment arm (rosiglitazone) or placebo. Patients will be initiated on 4 mg daily of rosiglitazone or matching placebo, with titration to the target dose of 8 mg daily or matching CLINICAL TRIAL DESIGN placebo one month later, if tolerated. Study drug will be added to existing therapy, and for patients taking insulin, the daily insulin dose will be decreased by 25% at the time of study drug initiation. Likewise, for those taking a sulphonylurea, the daily sulphonylurea dose will be decreased by at least 25% and not more than 50% at the time of study drug initiation. Assessment of glucose control will be made in all patients at baseline, monthly for the first three months and at study end by measuring glycosylated haemoglobin (HbA 1C ). Throughout the study, patients in both arms will be treated to a target HbA 1C < 7.0% using titration of openlabel non-TZD medications, with the aim of achieving similar levels of glucose control between the groups. 16 Compliance with study drug prescription will be determined by counting pills at each visit.
Study procedures and assessments
The schedule of study procedures and assessments is summarised in table 3.
Assessments at initial and final study visits
Prior to administration of the first dose of study drug, a comprehensive baseline evaluation will be performed that includes physical examination, measurement of waist and hip circumference, height (first visit only) and weight as well as duplicate averaged measurement of skin-fold thickness at the sub-scapular, biceps, triceps and supra-iliac areas to cal-culate percent body fat. 17 Each subject will complete the SF-36 quality-of-life questionnaire and a seven-day physical activity recall (PAR) questionnaire, 18 and will undergo a graded maximal CPX. Finally, a subset of patients (n=105) will undergo baseline cardiac MRI and MRS, as detailed below.
Final study visits will occur after six months of study drug therapy, with all baseline assessments repeated. In patients who develop significant symptoms of HF, final CPX and MRI exams will be performed, if possible, prior to discontinuing study drug for cardiac evaluation during the decompensated state, and will then be repeated several weeks after discontinuation of the study drug to assess for reversibility of symptoms and for any residual effect of the study drug.
Study visits
Study visits will occur at one, two, three and six months after the initial visit, with measurements of blood pressure, weight, waist and hip circumference and HbA 1C repeated at each visit. In addition, each follow-up visit will include an assessment for signs and symptoms of HF and peripheral oedema by a cardiologist. Based on the HbA 1C percentage, treatment will be titrated in both treatment arms, as previously specified. Concomitant medications will also be recorded. Any existing medications not prescribed for the purposes of glycaemic control will be continued throughout the study and will not be altered. Changes made to existing medications by subjects' primary care providers will be documented at each follow-up visit.
Laboratory assays
Standard clinical laboratory assessments will be made, including a comprehensive metabolic panel (CMP), complete blood count (CBC), and HbA 1C , at all study visits. Urinalysis with microalbumin measurement will be performed at the first and last study visits. Plasma and serum samples at baseline and study end will be multiply aliquoted and frozen at -70°C for subsequent analyses, including but not limited to assessment of BNP using a commercially available assay (Biosite Inc., San Diego, CA, US).
Cardiopulmonary exercise testing
A graded treadmill exercise test to exhaustion will be performed at baseline and after six months of study therapy for all subjects, using techniques standard in our laboratory for determination of VO 2peak . 19 ,20 A 12-lead ECG (Formula System, Biosound, Indianapolis, IN, US) will be used for continuous monitoring. To determine treadmill speed for each subject, a warm-up phase prior to the CPX will be performed during which each participant walks on the treadmill at an initial workload of 1.7 mph, 0% grade. Treadmill speed will be gradually increased until the participant can walk with a comfortable stride. Further adjustments in speed will be made until 60-70% of the participant's age-predicted maximal heart rate is achieved and/or until the participant reports a rate of perceived exertion (RPE) of 11-13 using the Borg scale. 21 Once an appropriate speed is reached, the treadmill speed will be recorded, and the participant will continue to walk at this speed for four minutes to become acclimatised to the treadmill. Following a 5-10 minute rest period, CLINICAL TRIAL DESIGN Given the high prevalence of obesity among diabetic patients and the likelihood that fat accumulation as a result of TZD use may confound assessment of oxygen consumption, the primary outcome of maximum oxygen consumption will be indexed to fat-free mass, a more accurate parameter among obese subjects. 20 In addition, in a subset of 20 patients, cardiac output (Qc) will be determined during maximal treadmill exercise using a standard inert gas rebreathing technique, with acetylene (C 2 H 2 ) as the soluble and helium as the insoluble gas. 19, 22, 23 Cardiac output will be measured at rest within 10 seconds of achieving maximal effort. The mean arterial pressure obtained during each cardiac output determination will be divided by the respective cardiac output to calculate total peripheral resistance. 24 Cardiac output will be divided by heart rate during rebreathing to estimate stroke volume. Oxygen uptake (VO 2 ) will be divided by cardiac output (CO) to calculate arteriovenous oxygen difference (AVDO 2 ) according to the Fick equation. 25 Cardiac magnetic resonance imaging (MRI) and spectroscopy (MRS) Cardiac MRI and MRS will be performed in a subset of two thirds of the enrolled subjects, the total to include approximately one third each of white, Hispanic and black participants. The sample size of 105 was determined based on statistical power to detect differences in myocardial triglyceride content (described below) within each ethnic subset. A standard cardiac imaging protocol previously described, 15 will include: (a) a scout image for determination of the cardiac long axis; (b) gradient-echo cine MRI long axis imaging; multiple short axis acquisitions spanning the ventricles (typically approximately 10 slices) for volume and mass; and (c) fourchamber and two-chamber cine MRI to determine systolic and diastolic function.
We will use cardiac localised MRS techniques developed by our group 26 to determine intra-myocardial triglyceride content at baseline and after six months of study drug treatment. Cardiac MRI and MRS studies will be performed using a whole body 1.5 T clinical scanner Gyroscan Intera (Philips Medical Systems, Cleveland, OH, US) equipped with a spectroscopy package. The method has been previously described. 26, 27 In short, we will use a combination of a whole body coil for radiofrequency transmission and a surface coil for signal reception. We will use a double-spin echo sequence (PRESS) with an echo time of 25 ms for spectral localisation and data collection, using respiratory gating at end-exhalation and ECG triggering at end-systole to eliminate motion artifacts. The volume for spectroscopic testing (6 cc) will be selected in the ventricular septum on cine images. The interpulse delay will be determined by respiratory cycle length (~5s). A signal from water in cardiac tissue will serve as an internal reference for chemical shift offset and for fat concentration. NUTS processing software (ACORNNMR-Freemont, CA, US) will be used for spectral line fitting procedures to calculate the spectral intensity of the resonance signals from myocardial water and from the methylene residues in the fatty acid chains of intra-myocardial triglyceride. The content of myocardial triglyceride will be expressed as a fat-to-water ratio. As described before, fatto-water ratios convert to µmol/g of wet tissue by using a conversion factor of 11.81.
Statistical plan
Determination of sample size The study will be powered according to the primary end point of peak oxygen uptake indexed to fat-free mass, with planned 150 patients to yield > 80% power at a two-sided level of significance of 0.05 to detect > 10% difference in VO 2peak . This estimate assumes a target population mean of VO 2peak (indexed to body mass) in the placebo control group of 32 ml/kg/minute (SD=7), based on data from more than 4,000 patients with T2DM who participated in a longitudinal cohort study at the Cooper Institute in Dallas (personal communication; Timothy S Church, October 2003). If the primary analysis demonstrates no statistical difference, a contingent non-inferiority analysis will be performed, with this sample size yielding > 80% power to establish non-inferiority of rosiglitazone (i.e. mean VO 2peak in rosiglitazone arm is not statistically lower than in placebo) at a minimal important difference of < 10% at the six-month evaluations.
For the secondary objective of evaluating the effect of rosiglitazone on myocardial triglyceride (mTG), we determined a priori that a relative difference of at least 30% in fat to water ratio would be of clinical relevance. The range of baseline mTG values from preliminary experiments in patients with diabetes was 0.25-1.4% in whites, 0.3-3% in Hispanics and 0.3 -1% in blacks. Therefore, 17 subjects per race-by-treatment assignment subgroup will provide > 80% power to detect a difference of > 30% change in fat-towater ratio assuming a 33% rate of technically inadequate studies (~51 subjects total per ethnic subset), yielding a net sample size of 105 for the MRS portion of the study.
Statistical and analytical plans Differences in the outcomes of interest will be compared using Student's t-test or Wilcoxon rank-sum for continuous and chi-squared or Fisher's Exact test for categorical variables. Within-group comparisons will be performed using paired t-tests. All analyses will be performed using the intention-to-treat principle. Univariable and multivariable logistic regression techniques will be used to evaluate predictors of peripheral oedema among patients treated with rosiglitazone. For analysis of the myocardial triglyceride data, repeated measures analysis of variance models will be used to include a grouping factor for treatment assignment and a repeated factor for paired measures, and models will be adjusted for key covariates associated with mTG. All statistical testing will be performed using two-tailed tests, at a significance level of 0.05. No corrections will be made for multiple comparisons.
Discussion
The use of TZDs is associated with weight gain, increased peripheral oedema, fluid retention and exacerbation of HF, observations that in aggregate have led to an FDA labelling modification for patients with heart failure in 2007 for both rosiglitazone and pioglitazone. The labelling consists of a caution for use in patients with any degree of HF and a contraindication for initiation in patients with New York Heart Association (NYHA) Class III or IV HF. These cautions are supported by a position statement from a joint panel of the American Diabetes Association (ADA) and the American Heart Association (AHA). 6 
Peripheral oedema
The reported incidence of new or worsening peripheral oedema associated with TZD use ranges from 2.5 to 16.2%, with risk increasing with increasing age, concomitant insulin use, higher doses of TZDs, female sex and declining renal function. 7, 8, [28] [29] [30] [31] [32] Despite the high incidence of new or worsening peripheral oedema and increased risk for HF, the mechanistic underpinnings of these observations remain unclear.
Among the most intriguing mechanisms that may contribute to TZD-associated peripheral oedema is enhanced sodium reclamation in the renal collecting duct resulting in plasma volume expansion. 12, 13, 33 Activation of PPARγ in epithelial cells lining the renal collecting duct increases expression of the epithelial sodium channel (ENaC)-γ and increases distal sodium reclamation and plasma volume, 13, 33 an effect that is eliminated in mouse models both by tissuespecific knockout of PPARγ in the kidney 12 and by concomitant treatment with the ENaC antagonist, amiloride. 13 Support for this hypothesis derives from a randomised trial assessing the effects of various diuretic medications on plasma volume measures in patients treated with rosiglitazone, where aldactone (an indirect ENaC antagonist) but not other diuretics reversed the plasma volume expansion associated with rosiglitazone. 34 These observations support the hypothesis that PPARγ-dependent sodium retention induces plasma volume expansion, and warrants further investigation.
The TZDs may also increase vascular permeability via antagonism of the L-type calcium channel, which is also the target of dihydropyridine calcium channel blockers known to be associated with peripheral oedema. 35 In addition, TZD use has been associated with increased circulating vascular endothelial growth factor (VEGF), which increases microvascular permeability. 36, 37 Therefore, it remains possible that some component of TZD-associated peripheral oedema is due to a peripheral capillary leak phenomenon.
New or worsening heart failure
Beyond peripheral oedema, a greater concern exists for the much less common but more serious incident or worsening HF associated with the TZDs, with a placebo-subtracted absolute increase in risk of approximately 0.25 to 0.45% per annum. 2, 6, 31, 32, 38 Whether these observations reflect direct cardiac toxicity, plasma volume overload or some combination thereof remains unclear.
Only a few randomised clinical trials have evaluated the cardiac effects of TZDs, all using echocardiographic parameters, in patients without 9,10 and with HF. 11 In these studies, no adverse effects on cardiac structure or function have been observed, and in one study, stroke volume index (32.4 vs. 34.9 ml/m 2 ; p<0.1) and cardiac index (2.4 vs. 2.6 ml/min/m 2 ; p<0.1) were improved with troglitazone treatment. The validity of the observations from these studies is notably uncertain due to open-label study design; 9,10 relatively small sample sizes; high attrition rates up to 60%; the use of echocardiographic assessments that are relatively insensitive to subtle changes in cardiac structure and function; and the assessment of cardiac parameters exclusively at rest. [9] [10] [11] Two randomised trials have assessed the effects of TZDs in the setting of prevalent HF. 7, 11 After 52 weeks of randomised treatment with rosiglitazone versus placebo in 224 patients with T2DM with decreased ejection fraction and NYHA Class I/II HF, peripheral oedema was increased in the rosiglitazone group (25.5 vs. 8.8%; p=0.037), as was use of HF medications. However, ejection fraction was not statistically different between the groups (36.3 vs. 37.1%; p=0.09), and an estimate of diastolic performance was significantly improved with rosiglitazone compared with placebo (E:A ratio 1.37 vs. 1.12; p=0.003). The effect of pioglitazone versus glyburide was assessed in a 24-week trial of patients with T2DM, impaired systolic function (EF < 40%) and NYHA Class II or III HF. This study was stopped prior to completion for reasons that have not been made public, and although not yet published, summary results are in the product label for pioglitazone. 7 The rate of hospitalisation for HF was numerically higher in the pioglitazone versus glyburide group (9.9 vs. 4.7%; no p-value provided). The effects on cardiac structure and function have not been reported.
In two large-scale randomised trials that enrolled patients with T2DM without HF but at increased CVD risk, increased incident HF associated with both pioglitazone and rosiglitazone has been reported. 31, 32, 38 Most recently, a meta-analysis of the rosiglitazone and pioglitazone HF data reported a 32% relative risk increment for HF with pioglitazone and a 218% relative increment with rosiglitazone. 4 Cardiopulmonary exercise testing Measurement of peak oxygen uptake (VO 2peak ) by cardiopulmonary exercise testing is a precise and reproducible method to assess integrated cardiovascular function, 39 and its use in the present study will complement the existing literature comprised of echocardiographic assessments at rest. In a previously published proof-of-concept study, treatment with rosiglitazone for four weeks in 20 subjects with T2DM resulted in a significant increase in maximal VO 2 ; however, this study was limited by a small sample size consisting primarily of low-risk individuals, relatively brief exposure to rosiglitazone, and use of correlated data analyses. 40 The present study is designed to assess these effects over a longer duration in a higher-risk cohort, with an adequate sample size to execute independent inter-group comparisons. In addition, in a subset of patients, we will perform non-invasive determinations of cardiac output to provide detailed assessment of effects of TZD on central (stroke volume) and peripheral (systemic vascular resistance) parameters of integrated cardiovascular performance.
Cardiac MRI techniques, which are more sensitive than previously reported echocardiographic assessments, will be used to assess cardiac structure, along with assessments of systolic and diastolic performance at rest. Cardiac MRI has excellent correlation with conventional measures of left ventricular (LV) function, as demonstrated in a study of 120 subjects with a broad range of ejection fraction. Compared with non-contrast echocardiography, contrast echocardiography and with cineventriculography, MRI estimates of ejection fraction yielded correlation coefficients of 0.60, 0.77 and 0.72, respectively, with inter-observation reliability most similar between MRI and contrast echocardiography. 41 With regard to ventricular mass estimates obtained by MRI versus echocardiography, in a study of 17 patients with hypertension, 42 using autopsy assessment as the gold standard, the precision of the MRI estimates for LV mass estimates was proven to be greater than double that obtained by echo, with greater inter-study reliability. We will further evaluate the cardiac contribution to incident peripheral oedema using a nested-case control comparison to evaluate all cardiovascular parameters between subjects who develop peripheral oedema versus those who do not. These comparisons will be complemented by assessment of serum BNP levels, which provide a sensitive serum marker of increased cardiac end-diastolic pressure, the hallmark of congestive heart failure.
Effect of rosiglitazone on myocardial lipid deposition
Normally, most triglyceride in the body is stored in adipose tissue, with little or no lipid accumulation in non-adipocytes due to high rates of fatty acid oxidation in other tissues. When this protective mechanism is defective, 43 large amounts of triglycerides accumulate in non-adipocytes, as demonstrated in pancreatic β-cells of obese Zucker rats, a genetic model of obesity, leading to β-cell apoptosis and eventually insulin deficiency. 43 Pancreatic steatosis in the pre-diabetic Zucker rats can be effectively reversed by the PPARγ antagonist, troglitazone. Ectopic deposition of triglyceride has also been demonstrated in cardiomyocytes in obese Zucker rats, associated with left ventricular systolic dysfunction, even before the development of frank diabetes. 44 Troglitazone effectively reverses myocardial steatosis and eliminates the decline in myocardial systolic function. Schick et al. were the first to demonstrate that fat in the form of droplets within myocytes can be distinguished from fat stored in adipose tissue cells interspersed between fibres in skeletal muscle using MRS techniques. 45 Subsequently, Boesch et al. reported similar findings using 1H-MRS for in vivo determination of intra-myocellular lipids in human skeletal muscle. 46 We evaluated this method first in animals, where we validated the method by direct biochemical measurements of triglycerides, 47 and then in humans, in both liver and skeletal muscle. 48 Other groups have used MRS to study myocardial triglyceride content in laboratory animals, [49] [50] [51] [52] [53] [54] [55] and demonstrated that the triglyceride content in isolated perfused rat hearts estimated by MRS correlates closely with chemically determined triglyceride content. We have adopted this technique to measure triglyceride in human hearts, with notable quality and reproducibility. 26, 27 In the present study, we will use these state-of-the art techniques developed by our group to evaluate the effects of rosiglitazone on intra-cardiac lipid content and assess how changes in triglyceride content relate to changes in cardiac function and integrated cardiovascular performance.
We have previously demonstrated the presence of detectable triglyceride in the myocardium of healthy men and women ranging in body mass index from 18 to 38 kg/m 2 . 26, 56 In overweight subjects, elevated myocardial triglyceride content was accompanied by increased LV mass and concentric LV compensatory remodelling. In addition to an association between increasing body mass index (BMI) and increasing myocardial triglyceride, we have also demonstrated increasing myocardial triglyceride with worsening glycometabolic status, independent of BMI, among subjects with impaired glucose tolerance and T2DM, and that cardiac steatosis was evident in the absence of perturbations of LV systolic function. 57 Lastly, we have observed racial disparities in the amount of mTG, with increasing mTG highly correlated with increasing BMI among white and Hispanic subjects, but little correlation among black subjects (unpublished data). Therefore, the present sub-study is designed: a) to evaluate the burden of baseline cardiac steatosis in a clinical cohort of patients with T2DM at elevated CVD risk; b) to assess the effect of rosiglitazone versus placebo on this measure; and c) to assess for disparities by race in burden and potential therapeutic response to rosiglitazone of cardiac steatosis.
Summary
Diabetes mellitus is associated with significant cardiovascular mortality and morbidity. Rosiglitazone and the TZD class of drugs remain a key component of the therapeutic armamentarium to treat hyperglycaemia associated with T2DM, yet their net cardiovascular effects are still incompletely understood. Ongoing concerns regarding the use of TZDs with regard to increased rates of peripheral oedema and HF yield great uncertainty with regard to clinical decision-making. The present study is designed to evaluate systematically the effects of rosiglitazone versus placebo on integrated cardiovascular performance, myocardial structure and function in a population of patients with T2DM at risk for developing congestive heart failure. Results from this study should have direct clinical application given the magnitude of the problem of T2DM and the incomplete understanding of the cardiovascular effects of rosiglitazone. 
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